In an effort to overcome the suboptimal clinical benefit of MKIs in RET-altered cancers, agerafenib (CEP-32496; RXDX-105) was developed as an orally available, ATP-competitive, selective inhibitor of RET and BRAF (262). The gene discussed is RET; the disease is cancer.